Business Medical Devices

The Undeniable Hemostasis Opportunity

Last updated: May 2, 2012 8:30 am

PatrickDriscoll

1 Min Read

Among many functions that wound management products might offer — wound closure, wound sealing, anti-infection, anti-adhesion, etc. — hemostasis represents a function that offers entry to the market by manufacturers of products derived from thrombin, gelatin, platelets, collagen, fibrin, fibrinogen, synthetics, etc.

Among many functions that wound management products might offer — wound closure, wound sealing, anti-infection, anti-adhesion, etc. — hemostasis represents a function that offers entry to the market by manufacturers of products derived from thrombin, gelatin, platelets, collagen, fibrin, fibrinogen, synthetics, etc.

Ideally, products offer multiple functions that will result in effectively closed and healed wounds with few complications. Nonetheless, the urgency with which bleeding must be stopped in acute wounds has driven the development of products that demonstrate important clinical utility simply by focusing on hemostasis rather than comprehensive wound management.

As a result, a good number of companies have emerged and become successful in the hemostasis niche.

Below is illustrated the distribution of companies active in marketing and/or developing products in hemostasis.

Hemostat-number-companies-2012

Source: MedMarket Diligence, LLC; Report #S190.

TAGGED:finance hemostasis

Share This Article

By PatrickDriscoll

Follow:

I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.